• HOME>
  • Investor Relations>
  • IR News>
  • Chemiphar and Sumitomo Dainippon Pharma Conclude Collaborative Research and Development Agreement and Option Agreement for Novel Antidepressant/Anxiolytic Candidate Compound "NC-2800"

IR News

Jun. 09, 2021Print(PDF/163KB)Licensing

Chemiphar and Sumitomo Dainippon Pharma Conclude Collaborative Research and Development Agreement and Option Agreement for Novel Antidepressant/Anxiolytic Candidate Compound "NC-2800"

We are pleased to announce that Nippon Chemiphar Co., Ltd. (Head Office: Chiyoda-ku, Tokyo; President and CEO, Kazushiro Yamaguchi; hereinafter, "Chemiphar") and Sumitomo Dainippon Pharma Co., Ltd. (Head Office: Osaka, Osaka; Representative Director, President and CEO, Hiroshi Nomura; hereinafter, "Sumitomo Dainippon Pharma") have concluded a collaborative research and development agreement and an option agreement for a novel antidepressant/anxiolytic candidate compound "NC-2800" (hereinafter, "this drug, " currently at non-clinical stage) that is under research and development by Chemiphar.

This drug is the subject of the research and development project "Development of innovative mood regulators with a mechanism of action based on activating opioid δ receptors," which was adopted under the Cyclic Innovation for Clinical Empowerment (hereinafter, "CiCLE") program of Japan Agency for Medical Research and Development (hereinafter, "AMED") in January 2018. Chemiphar moved forward with the research and development of this drug as a representative institution with the support of AMED.
Under the terms of the agreements, participating in the CiCLE R&D project as a contributing organization, Sumitomo Dainippon Pharma will collaborate with Chemiphar to advance the research and development of this drug. In addition, Sumitomo Dainippon Pharma has acquired the exclusive option right from Chemiphar to enter into a license agreement for development and marketing rights of this drug in worldwide territory once the development of this drug moves on to a phase 2b study.

With the conclusion of these agreements, the two companies will push ahead with the development of this drug from Japan that is expected to be highly innovative, to allow it to be delivered to patients worldwide as soon as possible.

Reference
1. About Chemiphar
Nippon Chemiphar was established in 1950 and is engaged in ethical pharmaceuticals, diagnostics and healthcare-related products. The Company continues to expand its business through strategic growth in the areas of generic drugs, alkalizer and in-house drug discovery in Japan and overseas. Regarding drug discovery, the Company is focused on developing new breakthrough drugs which has enabled it to successfully discover a number of hopeful compounds in recent years.
For more information, please visit: https://www.chemiphar.co.jp/english/

Overview
(1) Name Nippon Chemiphar Co., Ltd.
(2) Representative Kazushiro Yamaguchi, President and CEO
(3) Head Office 2-2-3, Iwamoto-cho, Chiyoda-ku, Tokyo, Japan
(4) Business Manufacture, sale, import and export of ethical pharmaceuticals and diagnostic agents; healthcare business
(5) Capitalization ¥4,304 million (as of March 31, 2021)
(6) Establishment June 16, 1950
(7) Fiscal year April 1 to March 31

2. About Sumitomo Dainippon Pharma
Sumitomo Dainippon Pharma defines it corporate mission as "to broadly contribute to society through value creation based on innovative research and development activities for the betterment of healthcare and fuller lives of people worldwide."
By channeling our efforts into the research and development of new drugs, we aim to realize our mission and provide innovative and effective pharmaceutical solutions not only to people in Japan but also around the world. Sumitomo Dainippon Pharma's goal is to create innovative pharmaceutical products in the focus research areas of psychiatry and neurology, oncology, and regenerative medicine/cell therapy.
For more information, please visit: https://www.ds-pharma.com/

Overview
(1) Name Sumitomo Dainippon Pharma Co., Ltd.
(2) Representative Hiroshi Nomura, Representative Director, President and CEO
(3) Head Office Osaka Head Office: 6-8, Doshomachi 2-chome, Chuo-ku, Osaka, Osaka, Japan
Tokyo Head Office: 13-1, Kyobashi 1-chome, Chuo-ku, Tokyo, Japan
(4) Business Manufacturing and sales of pharmaceuticals, food ingredients, food additives, veterinary medicines and others
(5) Capitalization ¥22.4 billion (as of March 31, 2021)
(6) Establishment May 14, 1897
(7) Fiscal year April 1 to March 31